Avenue Therapeutics, Inc. ATXI
0.50
0.14
38.89%
as of 24 Sep
- Market cap
- $680.0K
- P/E
- 0.0×
Follow ATXI
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | — | — | — | 0.00 |
P/S ratio |
— | — | — | — | — | — | — | — | — | 0.00 |
P/FCF ratio |
— | — | — | — | — | — | — | — | — | 0.00 |
P/Operating CF |
— | — | — | — | — | — | — | — | — | (2.49) |
P/B ratio |
— | — | — | — | — | — | — | — | — | 1.16 |
Price to Tangible BV |
— | — | — | — | — | — | — | — | — | 1.16 |
EV/Sales |
— | — | — | — | — | — | — | — | — | 0.00 |
EV/EBITDA |
— | — | — | — | — | — | — | — | — | 0.11 |
EV/Operating CF |
— | — | — | — | — | — | — | — | — | 0.18 |
EV/FCF |
— | — | — | — | — | — | — | — | — | 0.18 |
Quick Ratio |
0.03 | 7.81 | 0.52 | 4.13 | 3.54 | 7.57 | 1.87 | 1.49 | 3.18 | 2.60 |
Current Ratio |
0.03 | 7.95 | 0.88 | 4.22 | 3.66 | 7.78 | 1.91 | 1.55 | 3.27 | 2.67 |
Net Debt/EBITDA |
(0.81) | 1.94 | 0.12 | 0.33 | 0.60 | 1.01 | 0.83 | 0.12 | 0.23 | 0.93 |
Debt/Assets |
1,028.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.25) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 |
Operating CF/Net income |
0.51 | 0.55 | 0.85 | 1.01 | 0.90 | 1.01 | 2.14 | 0.91 | 0.77 | 0.63 |
Capex/Depreciation |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 47.48% | (220.23%) | (229.86%) | (839.94%) | (112.48%) | (128.43%) | (105.76%) | (529.44%) | (928.45%) | (157.75%) | |
| (3,011.37%) | (109.61%) | (161.44%) | (385.54%) | (84.72%) | (103.57%) | (65.75%) | (238.69%) | (515.35%) | (103.84%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
51.06% | (63.25%) | 3,414.90% | (381.00%) | (218.36%) | (108.11%) | (108.76%) | (1,586.70%) | (627.80%) | (158.79%) |
Average Days of Receivables |
— | — | — | — | — | 0.00 | — | — | — | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 73.86% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 260.19% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 47.36% |
Graham Net Nets |
— | — | — | — | — | — | — | — | — | 0.86 |
Graham Number |
— | — | — | — | — | — | — | — | — | 0.00 |
Earnings Yield |
— | — | — | — | — | — | — | — | — | (138.24%) |
Free Cash Flow Yield |
— | — | — | — | — | — | — | — | — | (86.09%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.45 |
Operating CF per Share |
(652.80) | (1,152.88) | (2,001.76) | (1,889.14) | (315.96) | (248.34) | (261.03) | (67.03) | (6.97) | (0.59) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(652.80) | (1,152.88) | (2,001.76) | (1,889.14) | (315.96) | (248.34) | (261.03) | (67.03) | (6.97) | (0.59) |
Cash per Share |
78.80 | 3,691.86 | 293.52 | 629.14 | 214.52 | 249.21 | 230.52 | 12.65 | 2.00 | 0.91 |
Shareholders Equity per Share |
(3,299.20) | 3,284.75 | (69.34) | 489.21 | 161.58 | 228.54 | 112.23 | 4.64 | 1.43 | 0.59 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(3,299.20) | 3,284.75 | (69.34) | 489.21 | 161.58 | 228.54 | 112.23 | 4.64 | 1.43 | 0.59 |
Free Cash Flow |
(1.63) | (6.80) | (18.22) | (26.26) | (4.61) | (3.75) | (7.60) | (9.45) | (9.03) | (1.83) |
Working Capital |
(6.22) | 19.38 | (0.63) | 6.80 | 2.36 | 3.45 | 3.27 | 0.65 | 1.86 | 1.83 |
Net Current Asset Value |
(8.25) | 19.38 | (0.63) | 6.80 | 2.36 | 3.45 | 3.27 | 0.65 | 1.86 | 1.83 |
EV/EBIT |
— | — | — | — | — | — | — | — | — | 0.11 |
Capex to Sales |
— | — | — | — | — | — | — | — | — | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (207.19%) |
Price to Operating Income |
— | — | — | — | — | — | — | — | — | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Cash ROIC |
27.09% | (16.52%) | (892.94%) | (168.92%) | (84.01%) | (51.98%) | (76.16%) | (387.81%) | (202.83%) | (39.11%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | — | — | — | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
0.50 | 1.62 | 3.70 | 2.89 | 0.99 | 0.70 | 0.74 | 0.79 | 0.71 | 0.95 |
Average Assets |
0.11 | 11.18 | 13.35 | 6.72 | 6.08 | 3.60 | 5.40 | 4.35 | 2.26 | 2.80 |
Average Common Equity |
(6.69) | 5.57 | 9.37 | 3.08 | 4.58 | 2.91 | 3.36 | 1.96 | 1.26 | 1.84 |
Columns are period end dates